Tarsus Pharmaceuticals, Inc. (TARS)

Market Cap	3.07B +40.9%
Revenue (ttm)	451.36M +146.7%
Net Income	-66.42M
EPS	-1.59
Shares Out	42.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120,670
Open	71.23
Previous Close	71.89
Day's Range	70.15 - 72.83
52-Week Range	38.51 - 85.25
Beta	0.63
Analysts	Buy
Price Target	89.00 (+23.41%)
Earnings Date	Apr 30, 2026

About TARS

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 370
• Stock Exchange: NASDAQ
• Ticker Symbol: TARS
• Website: https://tarsusrx.com

Financial Performance

In 2025, Tarsus Pharmaceuticals's revenue was $451.36 million, an increase of 146.71% compared to the previous year's $182.95 million. Losses were -$66.42 million, -42.52% less than in 2024.

Analyst Summary

According to 6 analysts, the average rating for TARS stock is "Buy." The 12-month stock price target is $89.0, which is an increase of 23.41% from the latest price.

Price Target

$89.0

(23.41% upside)

Analyst Consensus: Buy